Seed Tx was founded by Lan Huang, Avram Hershko, M.D., Lan Huang, Ph.D., Ning Zheng, Ph.D., Michele Pagano, M.D..

Who are Seed Tx's investors?

Seed Tx's investors include Eisai Innovation, Inc..

Where is Seed Tx headquartered?

Seed Tx is headquartered in King of Prussia, US.

Seed Tx

King of Prussia, US · 27 employees on LinkedIn · 1 known investors

Find your way into Seed Tx

Each arrow is one introduction. Sign up to fill in the first one.

801 people can intro you to Lan

Ask Jakob Dupont to introduce you to Lan Huang

You →Jakob · together at Memorial Sloan Kettering Cancer Center →Lan

Your email: who you already know at Seed Tx, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Seed Tx team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

SEED Therapeutics develops de novo molecular glue degraders for targeted protein degradation, using its RITE3 platform to match E3 ligases with disease-causing target proteins. Its lead RBM39 degrader (ST-01156) is in Phase 1 trials for Ewing sarcoma, hepatocellular carcinoma and related tumors, alongside additional oncology programs.

Biotech Deep Tech Healthtech

Founders & leadership

Lan Huang Ph.D.Lan Huang is a Co-founder, Chairman and CEO of Seed Therapeutics and Co-founder, Chairman and CEO of BeyondSpring Inc. (NASDAQ: BYSI), a cancer therapeutics company. With over 20 years in biotech, Huang has published in Science and Nature, holds multiple patents, and previously contributed research on E3 ligase structures and targeted protein degradation technology.

Avram Hershko, M.D.Co-Founder

Lan Huang, Ph.D.Co-Founder, CEO and Chairman

Ning Zheng, Ph.D.Co-Founder

Michele Pagano, M.D.Co-Founder

Investors · 1

Eisai Innovation, Inc.listed by Eisai Innovation, Inc.Cambridge · $5M

Frequently asked questions

What does Seed Tx do?: SEED Therapeutics develops de novo molecular glue degraders for targeted protein degradation, using its RITE3 platform to match E3 ligases with disease-causing target proteins. Its lead RBM39 degrader (ST-01156) is in Phase 1 trials for Ewing sarcoma, hepatocellular carcinoma and related tumors, alongside additional oncology programs.
Who founded Seed Tx?: Seed Tx was founded by Lan Huang, Avram Hershko, M.D., Lan Huang, Ph.D., Ning Zheng, Ph.D., Michele Pagano, M.D..
Who are Seed Tx's investors?: Seed Tx's investors include Eisai Innovation, Inc..
Where is Seed Tx headquartered?: Seed Tx is headquartered in King of Prussia, US.